Small molecule · developed by Ligand Pharmaceuticals
LGD-6972 (also coded MB-11262) is a sodium salt powder formulated in Captisol, a sulfobutylether beta-cyclodextrin excipient. It is studied in type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02851849 | Phase 2 | Type 2 Diabetes Mellitus | Completed | LGND |
| NCT02672839 | Phase 1 | Type 2 Diabetes Mellitus (T2DM) | Completed | LGND |
| NCT02250222 | Phase 1 | Type 2 Diabetes Mellitus | Completed | LGND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.
See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGND catalysts and pipeline →